your badges 52W Range $0–$3 1% of range Analyst Rating BUY 10 analysts Price Target $4 +2695% upside P/E · ROE · Net Profit Margin ·

MDCX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $0.16
Market Cap (MRQ) $6M
52W Range $0–$3

MDCX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

10-Year Performance Revenue, net income, margins and EPS trends

06
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend MDCX 5Y avg Peer Median Verdict
P/B (MRQ) 4.9 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -109.6%
Next Report Nov 09, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 10, 2026 $-0.21 $-0.13 -61.4%
March 31, 2026 May 14, 2026 $-0.31 $-0.20 -57.8%
Dec. 31, 2025 $-0.83 $-0.16 -430.7%
Sept. 30, 2025 $-0.65 $-0.30 -119.7%
June 30, 2025 $-0.42 $-0.26 -60.4%
March 31, 2025 $-0.42 $-0.24 -76.5%
Dec. 31, 2024 $-0.18 $-0.30 39.1%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
No annual filings for MDCX

We don't have SEC filings for this ticker yet.

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
No data for this statement

Not enough fundamentals data to build this statement yet.

Institutional owners (13F) 23 filers · $1.2M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 23
Value held $1.2M
New positions 9
Exited positions 7
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
9 (+2 vs prior Q) 7 (0 vs prior Q) 6 (0 vs prior Q) 4 (+1 vs prior Q) +302K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Interchange Capital Partners, LLC $718,376 1,586,871 61.47% Shares
JANE STREET GROUP, LLC $148,918 333,673 12.74% Shares
XTX Topco Ltd $108,612 243,362 9.29% Shares
Sterling Investment Advisors, Ltd. $44,630 100,000 3.82% Shares
COMMONWEALTH EQUITY SERVICES, LLC $23,490 52,643 2.01% Shares
May Hill Capital, LLC $22,593 50,622 1.93% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $14,041 31,462 1.20% Shares
STIFEL FINANCIAL CORP $13,389 30,000 1.15% Shares
JPMORGAN CHASE & CO $12,498 25,622 1.07% Shares
Wilmington Savings Fund Society, FSB $11,435 25,622 0.98% Shares
CITADEL ADVISORS LLC $11,203 25,102 0.96% Shares
Stratos Wealth Partners, LTD. $9,350 20,950 0.80% Shares
LPL Financial LLC $7,816 17,512 0.67% Shares
MARATHON CAPITAL MANAGEMENT $6,918 15,500 0.59% Shares
StoneX Group Inc. $6,365 17,066 0.54% Shares
Foundations Investment Advisors, LLC $4,909 11,000 0.42% Shares
OSAIC HOLDINGS, INC. $3,375 7,500 0.29% Shares
MORGAN STANLEY $456 1,022 0.04% Shares
JONES FINANCIAL COMPANIES LLLP $183 400 0.02% Shares
WELLS FARGO & COMPANY/MN $89 200 0.01% Shares
Smithfield Trust Co $11 24,614 0.00% Shares
HAZLETT, BURT & WATSON, INC. $0 425 0.00% Shares
ROYAL BANK OF CANADA $0 1,055 0.00% Shares

Company insiders 14 insiders · 6 officers · 9 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Raza Bokhari Chief Executive Officer June 3, 2026 A · 0 0 $0
Carolyn F. Bonner President and CFO June 3, 2026 A · 0 0 $0
James P. Quinlan Chief Financial Officer Aug. 13, 2025 M 274,147 0 0 $0
Andrew Alasdair Smith Chief Operating Officer June 3, 2026 A · 0 0 $0
Edward J. Brennan Chief Scientific Officer June 3, 2026 A · 0 0 $0
Faisal Mehmud Chief Medical Officer June 3, 2026 A · 0 0 $0
Cathy Mcmorris Rodgers Director June 3, 2026 A · 0 0 $0
Ajay Raju Director June 3, 2026 A · 0 0 $0
Sara R. May Director June 3, 2026 A · 0 0 $0
Larry Kaiser Director June 3, 2026 A · 0 0 $0
Robert J. Ciaruffoli Director June 3, 2026 A · 0 0 $0
Barry Fishman Director June 3, 2026 A · 0 0 $0
William Ashton Director June 3, 2026 A · 0 0 $0
Patrick J Mahaffy Director June 3, 2026 A · 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

MDCX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 10 analysts BUY
Median target $4.00 +2384.5%
2 20.0% Strong Buy
7 70.0% Buy
1 10.0% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

4 analysts · 2026-10-02

Mean target $4.50 +2695.0%

← Below all targets Current price $0.16
Low$1.00 Mean$4.50 High$9.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
MDCX · · · · · ·
PBM · -0.2 · · · ·
XENE $3.59B -10.3 · -4612.1% -56.9% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed May 14, 2026